Michael Hofman

Company: Peter MacCallum Cancer Centre

Job title: Director - Prostate Cancer Theranostics & Imaging Centre of Excellence

Seminars:

Utilizing Diagnostics to Inform Patient Stratification and Selection in Clinical Trials 11:30 am

Molecular imaging with PET/CT provides immense value for both patient selection and as a prognostic/predictive biomarker For PSMA theranostics, the value of FDG in addition to PSMA PET/CT will be highlighted It is particularly critical for phase I/II to enrich patients likely to benefit from therapyRead more

day: Day One